Blue Light, Wrong Room

Severe neonatal jaundice (hyperbilirubinemia) causes an estimated 114,000 deaths and 63,000 cases of kernicterus (permanent brain damage) per year, with >90% of the burden in sub-Saharan Africa and South Asia. Phototherapy — exposure to blue-spectrum light that converts bilirubin to water-soluble forms — is a simple, highly effective treatment available in virtually every high-income neonatal unit. But conventional phototherapy devices consume 60-300 watts, generate significant heat requiring climate control, use specialized fluorescent or LED arrays that dim over time without irradiance monitoring, and cost $2,000-15,000. In LMIC hospitals, power outages interrupt treatment, overheating from devices in un-air-conditioned rooms causes neonatal hypothermia or hyperthermia, burned-out lamps go unreplaced, and bilirubin measurement devices (bilirubinometers) needed to guide treatment are unavailable.

Jaundice is the single most common reason for hospital readmission in the first week of life worldwide. In high-income countries, mortality from severe jaundice is near zero due to universal screening and readily available phototherapy. The 114,000 deaths per year occur almost entirely in settings where phototherapy is either unavailable, non-functional, or inadequate. The UNICEF/NEST360 TPPs cover both the phototherapy light and the bilirubinometer — because treatment without bilirubin monitoring leads to both undertreatment (missing dangerous levels) and overtreatment (occupying scarce devices unnecessarily).

Low-cost phototherapy devices have been developed by multiple groups (e.g., Brilliance Pro by D-Rev, Firefly by Design that Matters), demonstrating that effective phototherapy can be delivered at $400-500 per unit. But deployment reveals persistent challenges: LED arrays degrade over thousands of hours, and without built-in irradiance sensors, clinicians cannot tell when the device is no longer delivering therapeutic light levels. Many facilities lack even basic bilirubin testing — transcutaneous bilirubinometers cost $3,000-7,000 and require calibration. The result is phototherapy by guesswork: treatment initiated based on visual inspection of skin color (unreliable, especially in dark-skinned infants) and continued for arbitrary durations. Donated HIC phototherapy units face the same failure modes as other donated equipment: no replacement parts, no service contracts, device failure within months.

The NEST360 TPP specifies: phototherapy devices with >=30 microwatts/cm2/nm irradiance across the treatment area, built-in irradiance monitoring and low-output alerts, <=50W power consumption, battery backup for >=4 hours, operational at 15-40 degrees C and up to 95% RH, and a cost enabling national-scale procurement. For bilirubinometers, the TPP specifies: transcutaneous measurement accurate across all skin pigmentations, no consumables required per test, and battery-powered operation. Meeting both specs simultaneously would enable a closed-loop jaundice management system — measure, treat, monitor — in facilities with minimal infrastructure.

A team could design a phototherapy device with integrated irradiance self-monitoring: an LED array with embedded photodiode sensors that continuously measure delivered irradiance at the infant plane and alert when output drops below therapeutic thresholds, eliminating the reliance on external light meters. The engineering challenge is calibrating embedded sensors against clinical-grade irradiance standards while maintaining manufacturing costs below $500. Alternatively, a team could prototype a low-cost transcutaneous bilirubinometer using smartphone-based spectrophotometry, evaluating accuracy across simulated skin pigmentation levels from Fitzpatrick types I through VI. Relevant disciplines: optical engineering, biomedical engineering, neonatology, electronic design.